Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials
Open accessAbstract
BACKGROUND: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. In previous trials, apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran reduced triglyceride levels. However, the three medications' safety and efficacy have yet to be compared. METHODS: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane until November 22nd, 2024. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. RESULTS: Ten RCTs with a total of 1,129 patients were included. volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Only plozasiran once monthly, regardless of the dose, showed a non-significant percent reduction in triglycerides. This finding should be taken cautiously as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo, with plozasiran 100 mg monthly and volanesorsen 300 mg once weekly showing the most significant reduction (MD range: -92.8% to -88.5%; P < 0.01). None of the treatments showed a statistically significant difference in overall adverse events rate compared to the placebo. CONCLUSION: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride and APOC3 levels in hypertriglyceridemia with an acceptable safety profile. However, the results should be interpreted cautiously due to the small sample size. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and show strong evidence of the impact of each regimen.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ASO studies targeting APOC3 showed similar TG-lowering effects with dose-dependent safety considerations.
“ASO studies targeting APOC3 showed similar TG-lowering effects with dose-dependent safety considerations (Mahmoud et al., 2025).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Mahmoud et al., 2025
The Results (Efficacy outcomes; page unavailable) report triglyceride reductions with several APOC3-targeting ASOs, but not similar effects across regimens: volanesorsen 300 mg weekly had the largest reported reduction, and some plozasiran regimens were not statistically significant. The Results (Safety outcomes; page unavailable) and Conclusion associate higher-dose volanesorsen with injection-site reactions and thrombocytopenia, supporting dose-related safety considerations for that drug, not necessarily for all the ASOs studied. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 33,583 · see citing works
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 1× · see citing works
“To estimate the quality of evidence, two reviewers adopted the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) instructions [35, 36].”
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218 · see citing works
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1× · see citing works
“However, its scope is limited in ASCVD patients, as it does not lower LDL, a crucial component in ASCVD pathogenesis [58–61].”
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250 · see citing works
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2× · see citing works
“However, cardiovascular and pancreatic outcome trials are essential to position such a regimen within the existing treatment paradigm for HTG [8, 9, 45, 46].”
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751 · see citing works
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116 · see citing works
Loss-of-Function Mutations in <i>APOC3</i> and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · see citing works
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · cited 1× · see citing works
“Therefore, volanesorsen can be recommended in cases of severe HTG or those at risk of acute pancreatitis or high TG-related cardiovascular diseases [42–44].”
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669 · see citing works
Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A. (2018) · JAMA · doi:10.1001/jama.2018.2525 · Cited by 549 · see citing works
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528 · see citing works
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491 · see citing works
The Role of Triglycerides in Atherosclerosis
Talayero, B., & Sacks, F. M. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0220-3 · Cited by 356 · see citing works
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400201 · Cited by 271 · cited 1× · see citing works
“Four of these studies investigated the effects of volanesorsen [18, 25, 26, 38], three examined the impact of Plozasiran [19, 37, 40], and the remaining three studied olezarsen [20, 39–41].”
Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00046-2 · Cited by 232 · see citing works
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · see citing works
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404143 · Cited by 210 · see citing works
Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210 · see citing works
Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening
Singh, S., & Bittner, V. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0482-5 · Cited by 198 · see citing works
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402309 · Cited by 198 · see citing works
HDL-mediated mechanisms of protection in cardiovascular disease
Kontush, A. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu147 · Cited by 194 · see citing works
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194 · see citing works
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0159-y · Cited by 188 · see citing works
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182 · see citing works
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0959 · Cited by 172 · see citing works
Hypertriglyceridemia and acute pancreatitis
Murphy, M. J., Sheng, X., MacDonald, T. M., & Wei, L. (2013) · JAMA Internal Medicine · doi:10.1001/2013.jamainternmed.477 · Cited by 172 · see citing works
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170 · see citing works
Remnant Lipoproteins As Strong Key Particles to Atherogenesis
Fujioka, Y., & Ishikawa, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e598 · Cited by 146 · see citing works
Elevated LDL Triglycerides and Atherosclerotic Risk
Balling, M., Afzal, S., Smith, G. D., Varbo, A., Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.019 · Cited by 115 · see citing works
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103 · see citing works
Genetics of familial combined hyperlipidemia and risk of coronary heart disease
Shoulders, C. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh069 · Cited by 96 · see citing works
The Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 95 · see citing works
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 81 · see citing works
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80 · see citing works
Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia
Christian, J. B., Arondekar, B. V., Buysman, E. K., Jacobson, T. A., Snipes, R., & Horwitz, R. I. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.09.018 · Cited by 77 · see citing works
Oral, E. A., Garg, A., Tami, J. A., Huang, E. A., O'Dea, L. S. L., Schmidt, H., Tiulpakov, A. N., Mertens, A. C., Alexander, V. J., Watts, L. M., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.008 · Cited by 75 · see citing works
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200325 · Cited by 71 · see citing works
Langlois, M. R., & Sniderman, A. D. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01323-z · Cited by 69 · see citing works
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54 · see citing works
APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia
Schmitz, J., & Gouni‐Berthold, I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170609081612 · Cited by 43 · see citing works
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 43 · see citing works
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?
Ferhatbegović, L., Mršić, D., Kušljugić, S., & Pojskić, B. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01037-3 · Cited by 41 · see citing works
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35 · see citing works
Dyslipidemia and the Metabolic Syndrome
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.3009 · Cited by 32 · see citing works
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27 · see citing works
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [33]Covidence. Covidence - Better systematic review management [Internet]. Covidence. 2024. https://www.covidence.org/
Cited by
Sorted by citations
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9 · see citing works
Gao, Y., Bai, Y., Mu, X., & Pang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736821 · Cited by 4 · see citing works
Dong, J.-X., Sun, M., Li, Y.-M., & Xie, Z. (2025) · Journal of drug targeting (Print) · doi:10.1080/1061186x.2025.2544786 · Cited by 3 · see citing works
Loomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70623 · Cited by 4 · see citing works
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 2 · see citing works
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1 · see citing works
Yoo, J. H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e19 · Cited by 1 · see citing works
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1 · see citing works
Innovative regenerative genetic and nano therapies for diabetes and metabolic disease
Spanorriga, M., Fragoulis, C., Bega, I., Mavromoustakou, K., Gatsouniotis, I., Lontou, S.-P., Dimitriadis, K., Aznaouridis, K., Ktenopoulos, N., Thanopoulou, A., et al. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101461 · Cited by 1 · see citing works
Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD
Messer, E. K., Fischer, J., Herta, T., Boehlig, A., Matz‐Soja, M., Tuennemann-Tarr, A., Gaul, S., Laufs, U., & Berg, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349666 · Cited by 1 · see citing works
PharmD, L. T., Trampoukis, C., & Polymenakos, K. (2025) · medRxiv · doi:10.1101/2025.07.16.25331632 · Cited by 1 · see citing works
Teperikidis, E., Trampoukis, C., & Polymenakos, K. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001768
Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.052
Soran, H., Kessler, A. S., Vera-Llonch, M., Alexander, V. J., Serafini, P., Pushkarna, D., Rodrigues, E., Stroes, E. S. G., Schatz, U., Kassner, U., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0069
Österreichischer Lipidkonsensus 2026
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Karimi, M., Tahmasebi, A., Ramezanipour, S., Rad, F. N., Valizadeh, F., Abedi, P., Gholami, M., Ardekani, N. S., & Pirshahid, M. E. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70294
Coan, A. C. C., Katsuyama, E. S., Lopes, R. A., Sanchez, C. V., Prata, A. A., Fukunaga, C. K., Talavera, A., & Shapiro, M. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105022
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
- Authors
- Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D.
- Affiliations
- Minia University (EG)
- Magdi Yacoub Heart Foundation (EG)
- University of Minnesota (US)
- University Elmergib (LY)
- Almaarefa University (SA)
- Hennepin County Medical Center (US)
- King Edward Medical University (PK)
- West Virginia University (US)
- Corresponding author
- Abdelsayed, Kerollos
- ORCID
- Venue
- Lipids in Health and Disease
- Published
- 2025-03-22
- Volume
- 24
- Issue
- 1
- Pages
- 109-109
- ISSN
- 1476-511X (ISSN-L)
- PMC
- PMC11929262
- OpenAlex
- W4408706982
- Cited by
- 17
- References
- 60
- Citations by year
- 2026: 11 · 2025: 6
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Lipids in Health and Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, antisense oligonucleotides, apolipoprotein C-III, volanesorsen, olezarsen, plozasiran, triglyceride lowering, lipid-lowering therapy, drug safety, cardiovascular risk
- MeSH terms
- Network Meta-Analysis as Topic, Humans, Oligonucleotides, Triglycerides, Hypertriglyceridemia, Randomized Controlled Trials as Topic, Oligonucleotides, Antisense, Treatment Outcome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
